Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia

A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage therapy for these patients. We studied all adult pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Canaani, Jonathan, Nagar, Meital, Heering, Gabriel, Gefen, Chen, Yerushalmi, Ronit, Shem-Tov, Noga, Volchek, Yulia, Merkel, Drorit, Avigdor, Abraham, Shimoni, Avichai, Amariglio, Ninette, Rechavi, Gidi, Nagler, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289527/
https://www.ncbi.nlm.nih.gov/pubmed/32577167
http://dx.doi.org/10.18632/oncotarget.27618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289527/
https://www.ncbi.nlm.nih.gov/pubmed/32577167
http://dx.doi.org/10.18632/oncotarget.27618

Ejemplares similares